Moderator: Khushita Vasant

Khushita covers US antitrust enforcement and litigation for MLex in Washington, DC. She previously covered EU competition law in Brussels where she broke news on high-profile antitrust and merger investigations. She has covered the EU’s actions against Google, Apple, Facebook, and Amazon, to name a few. Now in the US, she closely tracks landmark antitrust lawsuits and investigations initiated by the Department of Justice and Federal Trade Commission against some large digital platforms. She’s often in federal courts across the US to report on high-profile civil and criminal antitrust litigation, and on Capitol Hill to cover developments on a set of critical antitrust bills pending in Congress. Khushita specializes in coverage of intellectual property, with notable scoops on US policy developments and EU investigations in the field of standard-essential patents. Her articles on SEPs have been nominated for the Concurrences Antitrust Writing Awards. Khushita previously wrote about monetary policy, and the bond and FX markets for The Wall Street Journal and Dow Jones Newswires in Mumbai.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More